Tinkeso Therapeutics Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
2
- Latest Deal Type
-
Seed
- Investors
-
5
Tinkeso Therapeutics General Information
Description
Operator of a biotechnology company intended to develop innovative therapies for the treatment of autoimmune diseases and cancers. The company focuses on creating off-the-shelf, allogeneic chimeric antigen receptor (CAR) engineered natural killer T (NKT) cell therapies, which use NKT cells to target and destroy cancer cells or modulate the immune response in autoimmune conditions, enabling healthcare professionals to offer treatment options based on non-patient-specific cells, increasing accessibility and scalability.
Contact Information
Website
www.tinkeso.comCorporate Office
- 40 Sunshine Cottage Road
- Valhalla, NY 10595
- United States
Corporate Office
- 40 Sunshine Cottage Road
- Valhalla, NY 10595
- United States
Tinkeso Therapeutics Timeline
Tinkeso Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Seed Round | 04-Sep-2024 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 01-Apr-2024 | Completed | Startup | |||
| 1. Grant | 01-Jul-2023 | $398K | Completed | Startup |
Tinkeso Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Tinkeso Therapeutics Patents
Tinkeso Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4482501-A1 | Modified invariant natural killer t cells expressing a chimeric antigen receptor and uses thereof | Pending | 23-Feb-2022 | ||
| EP-4482501-A4 | Modified invariant natural killer t cells expressing a chimeric antigen receptor and uses thereof | Pending | 23-Feb-2022 | ||
| US-20250170240-A1 | Modified invariant natural killer t cells expressing a chimeric antigen receptor and uses thereof | Pending | 23-Feb-2022 | A61K40/15 |
Tinkeso Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Tinkeso Therapeutics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| IndieBio | Accelerator/Incubator | Minority | ||
| SOSV | Venture Capital | Minority | ||
| National Cancer Institute I-Corps | Accelerator/Incubator | |||
| Small Business Innovation Research and Small Business Technology Transfer Programs | Government | |||
| BioInc@NYMC | Accelerator/Incubator |
Tinkeso Therapeutics FAQs
-
When was Tinkeso Therapeutics founded?
Tinkeso Therapeutics was founded in 2016.
-
Where is Tinkeso Therapeutics headquartered?
Tinkeso Therapeutics is headquartered in Valhalla, NY.
-
What is the size of Tinkeso Therapeutics?
Tinkeso Therapeutics has 2 total employees.
-
What industry is Tinkeso Therapeutics in?
Tinkeso Therapeutics’s primary industry is Drug Discovery.
-
Is Tinkeso Therapeutics a private or public company?
Tinkeso Therapeutics is a Private company.
-
What is Tinkeso Therapeutics’s current revenue?
The current revenue for Tinkeso Therapeutics is .
-
Who are Tinkeso Therapeutics’s investors?
IndieBio, SOSV, National Cancer Institute I-Corps, Small Business Innovation Research and Small Business Technology Transfer Programs, and BioInc@NYMC have invested in Tinkeso Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
